US setback for AstraZeneca drug

12 April 2012

PHARMACEUTICAL group AstraZeneca's prostate cancer treatment Casodex has received a setback from the US's drug authority.

The Food and Drug Administration has turned down the group's application to market Casodex in the US for the treatment of early prostate cancer. However, AstraZeneca said it was hopeful this was just a 'temporary setback'.

It added that the decision did not impact on current use and approval of the drug for advanced prostate cancer.

A spokesman said: 'In some ways it is (a setback) but Casodex is already well established worldwide. This isn't the primary application, its a supplementary application. Hopefully this will be a temporary setback and we can work with the FDA and resolve the differences,' he said.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in